Skip to main content
. 2020 Sep 29;10:573822. doi: 10.3389/fonc.2020.573822

Table 1.

Patients baseline and therapy-related characteristics.

Patient Age Diagnosis Donor Type GVHD before relapse Time from transplant to relapse Therapy after relapse Blasts in BM before CAR-T Therapy (%) Blasts in PB before CAR-T Therapy (%) Donor chimerism (BM) (%) Time from relapse to CAR-T therapy Time from stop immuno-suppressive therapy to CAR-T therapy
Pt1# 41–45 B-ALL (Ph+) MMUDT (8/10) Grade I aGVHD, cGVHD 58 months TKI 60.4 36.5 8.82 0.5 months 51 months
Pt 2# 46–50 B- ALL MSDT Grade II aGVHD, cGVHD 18 months No 26.2 16.4 20.55 0.5 months 7 months
Pt 3# 56–60 B-ALL Haplo-HSCT (7/10) Grade I aGVHD 11 months No 5.6 2.6 79.12 1 months 9 months
Pt 4# 31–35 B-ALL Haplo-HSCT (5/10) No 5 months No 68.8 46.5 39.35 0.5 months 3 months
Pt 5# 21–25 B-ALL Haplo-HSCT (5/10) Grade I aGVHD, cGVHD 15 months No 45.2 22.9 48.36 0.5 months 6 months
Pt 6# 16–20 B-ALL MUDT Grade II aGVHD 4 months Two courses 58.4 39.4 23.12 2 months 3 months
Pt 7# 11–15 B-ALL (Ph+) Haplo-HSCT (5/10) No 6 months No 16.2 8.6 83.02 1 months 5 months
Pt 8# 11–15 B-ALL MSDT Grade I aGVHD 14 months One course 32.8 16.8 77.13 1 months 9 months
Pt 9# 21–25 B-ALL (Ph+) Haplo-HSCT (5/10) No 13 months TKI 48.6 33.5 36.18 0.5 months 11 months
Pt 10# 56–60 B-ALL MSDT Grade I aGVHD 9 months Two courses 52.4 50.4 52.08 3 months 4 months
Pt 11# 21–25 B-ALL MSDT No 24 months No 40.8 29.8 50.25 0.5 months 20 months
Pt 12# 16–20 B-ALL (Ph+) Haplo-HSCT (5/10) Grade I aGVHD 9 months TKI 82.0 66.8 29.14 1 months 4 months
Pt 13# 21–25 B-ALL Haplo-HSCT (5/10) Grade II aGVHD 15 months Three courses 12.8 8.8 85.16 6 months 6 months
Pt 14# 16–20 B-ALL Haplo-HSCT (5/10) Grade II aGVHD 7 months No 40.2 25.5 56.75 0.5 months 3 months
Pt 15# 11–15 B-ALL Haplo-HSCT (5/10) Grade I aGVHD 5 months No 65.5 45.6 42.47 0.5 months 0.5 months

HLA-matched sibling donor transplantation, MSDT; HLA-matched unrelated donor transplantation, MUDT; HLA-mismatched unrelated donor transplantation, MMUDT; Haploid donor transplantation, Haplo-HSCT; Tyrosine kinase inhibitor, TKI.

Chemotherapy after relapse: Pt 6# Two courses of VDCP. Pt 8# One course of VCP. Pt 10# One course of FLAG and one course of VDCP.

Pt 13# Two courses of Hyper-CVAD and one course of FLAG.